A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies

Sattva S. Neelapu, MD1, Don A. Stevens, MD2, Mehdi Hamadani, MD3, Matthew J Frank, MD, PhD4, Houston Holmes, MD, MBA5*, Aya Jacobovits, PhD6*, John Hinkle, PhD7*, Jackie Kennedy-Wilde, MS6*, Ori Maller, PhD6*, Bayarmagnai Weinstein, MD, PhD6*, Francesco Galimi, MD, PhD6, Rose K Lai, MD6* and David B. Miklos, MD, PhD4

1Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX; 2Norton Healthcare, Norton Cancer Institute, Louisville, KY; 3BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI; 4Blood and Marrow Transplant and Cell Therapy Program, School of Medicine, Stanford University, Palo Alto, CA; 5Baylor Charles A. Sammons Cancer Center, Dallas, TX; 6Adicet Therapeutics Inc, Redwood City, CA; 7EarlyPhase Sciences Inc, Austin, TX

Introduction: ADI-001 is a first-in-class allogeneic gamma delta (γδ) CAR T cell therapy targeting the B-cell antigen CD20. ADI-001 has both adaptive and innate cytotoxic effector functions to complement CAR targeting, potentially enhancing efficacy and reducing the possibility of tumor escape due to antigen loss. ADI-001 expresses MHC-independent γδ T cell receptors, thus lowering the risk of graft-versus-host disease (GvHD) without the need for gene editing.

Methods: This multicenter phase 1 clinical trial is evaluating ADI-001 in adults with relapsed / refractory B-cell lymphoma. Eligibility criteria included the presence of measurable lesions, expression of CD20 on tumor cells and ≥ 2 prior systemic therapies. All patients received conditioning therapy with fludarabine and cyclophosphamide. ADI-001 can be administered at four
dose levels (DL) (DL1:3E7, DL2:1E8, DL3:3E8 and DL4:1E9 CAR+ cells) in a 3+3
dose-escalation scheme. Patients who completed the 28-day DLT period
were considered evaluable. In DL3, patients could receive a second course
of conditioning therapy and be re-dosed with ADI-001 if there was no DLT
during the first 28 days, no progressive disease on PET/CT assessment on
Day 28, and have recovered from cytopenias. Treatment-emergent adverse
events were graded by CTCAE v5.0, and Immune Effector Cell Associated
Neurologic Syndrome (ICANS) and Cytokine Release Syndrome (CRS)
assessments were performed per ASTCT criteria. Objective response rates
(ORR) were evaluated by independent radiographic review per Lugano 2014
criteria.

Results: As of 15 July 2022, 11 patients were enrolled and nine were
evaluable. Of these nine patients, six (67%) were male and the median age
was 62 years (range 45-75). Eight patients had large B-cell lymphoma (LBCL)
and one had mantle cell lymphoma (MCL). Of the eight patients with LBCL,
five had diffuse-large B-cell lymphoma (DLBCL), two had high-grade B-cell
lymphoma (HGBCL) with double/triple hit, and one had HGBCL not
otherwise specified. At baseline, the median IPI score was four (range 2-4);
the median tumor burden was 2,974 (150-7,919) mm², and 89% (8/9) had
stage III/IV disease. The median number of prior therapies was four (range
2-5). Four patients had prior anti-CD19 CAR T cell therapy (two Liso-cel and
two Axi-cel). Among nine evaluable patients, three patients were treated at
each of DL1, DL2, and DL3. Two patients at DL3 were re-dosed with a second
course of ADI-001.

Two patients developed CRS: one Grade 1 and one Grade 2. One patient
developed a Grade 1 ICANS which resolved within 24 hours. There were no ≥
Grade 3 CRS or ICANS. The only related SAEs were Grade 2 CRS, Grade 1
ICANS and Grade 3 adenoviraemia. There was no reported GvHD or
protocol-defined DLT events. The best ORR was 78% (7/9), and the complete
response (CR) rate was 78% (7/9). For the four patients who had prior CD19
CAR T therapies, the ORR was 100% (4/4) and CR rate was also 100%. As of
the data cut-off date, of the seven patients who had achieved CR, two
patients progressed, one died while in complete remission and four were
still in CR and in active follow-up, with a range of follow-up time between 1.2
and 8.8 months. CAR+ γδ T cell kinetics improved in a dose-dependent
manner with peak cell expansion occurring between Days 7 and 10 at DL3
based on flow cytometry.

Conclusions: ADI-001 γδ CAR T cells maintained a favorable safety profile.
Preliminary efficacy showed encouraging CR rate and sustained durability in
patients, including those previously exposed to CAR T therapy. Additional data will be presented at the meeting.